OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

COMMENTED

Macular Diseases

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Am J Ophthalmol.

Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, Pertile G

doi: 10.1016/j.ajo.2018.08.004.

Macular Diseases

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

Ophthalmologica.

Farinha C, Martins A, Neves A, Soares R, Ruão M, Ornelas M, Neves P, Gomes Rodrigues F, Coelho C, Silva R

doi: 10.1159/000489046.

Macular Diseases

Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method

Acta Ophthalmol.

Cao J, You K, Jin K, Lou L, Wang Y, Chen M, Pan X, Shao J, Su Z, Wu J, Ye J

doi: 10.1111/aos.14514.

Macular DiseasesRetinal Diseases

Long-term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes with Diabetic Macular Edema treated with Anti-VEGF Therapy

Am J Ophthalmol

Borrelli E, Grosso D, Barresi C, Lari G, Sacconi R, Senni C, Querques L, Bandello F, Querques G

doi: 10.1016/j.ajo.2021.09.002

Macular Diseases

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Ophthalmology.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA

doi: 10.1016/j.ophtha.2017.10.010.

Macular Diseases

Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study

Acta Ophthalmol.

Granstam E, Rosenblad A, Modher Raghib A, Granström T, Eriksson JW, Lindholm Olinder A, Leksell J

doi: 10.1111/aos.14290.

Macular Diseases

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Clin Exp Ophthalmol.

Spooner K, Fraser-Bell S, Hong T, Chang A

doi: 10.1111/ceo.13636.

COMMENTED

Macular DiseasesRetinal DiseasesFurther Publications

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Ophthalmol Retina

Gallardo M, Munk MR, Kurmann T, De Zanet S, Mosinska A, Karagoz IK, Zinkernagel MS, Wolf S, Sznitman R

doi: 10.1016/j.oret.2021.05.002

Macular DiseasesRetinal Diseases

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study

Acta Diabetol.

Busch C, Fraser-Bell S, Zur D, Rodríguez-Valdés PJ, Cebeci Z, Lupidi M, Fung AT, Gabrielle PH, Giancipoli E, Chaikitmongkol V, Okada M, Laíns I, Santos AR, Kunavisarut P, Sala-Puigdollers A, Chhablani J, Ozimek M, Hilely A, Unterlauft JD, Loewenstein A, Iglicki M, Rehak M; International Retina Group

doi: 10.1007/s00592-019-01310-z.

Related content

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method

Long-term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes with Diabetic Macular Edema treated with Anti-VEGF Therapy

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study